Highlights

  • Canada is the exception, and it is worth being precise here.
  • Immuron's disclosed cash position was AUD 10.0 million at 31 December 2025, which the company described as about 22.5 months of cash…
  • Half-year FY26 EBITDX excluding Research and Development was negative AUD 1.1 million, and Immuron received an AUD 1.1 million research and development…
  • Immuron lodged its FY25 Appendix 4E on 29 August 2025, so audited FY26 accounts would ordinarily be expected around the end…

Immuron reported on 16 July that global Travelan sales reached AUD 7.7 million in FY26, up 6 %, marking four consecutive quarters of year-on-year growth. For a company with a Market Value of about AUD 11 million, a steady commercial product is the most Tangible Asset it has.

Company Overview

Immuron is a Melbourne-based biopharmaceutical company working with orally delivered polyclonal antibodies derived from bovine colostrum. Its commercial product, Travelan, is an over-the-counter supplement sold to reduce the risk of travellers' diarrhoea. Australia is the core market, with the United States and Canada the main export destinations, and the company also distributes ProIBS for irritable bowel syndrome symptoms under an exclusive Australia and New Zealand agreement.

Recent Developments

The FY26 sales report is the immediate news. Global Travelan Revenue of AUD 7.7 million was 6 % ahead of FY25. Second-half sales were AUD 3.5 million, up 7 %, and fourth-quarter sales were AUD 2.0 million, up 2 %.

The regional split matters more than the total. Australia, the largest market, delivered AUD 5.8 million, up 10 %, which the company attributed to digital and Social Media Marketing , same-store growth, new banner group stores and increased South East Asian travel, with new packaging launched in the June quarter. The United States contributed AUD 1.8 million, up 7 % in Australian dollars and 13 % in US dollar…

Financial Snapshot

Immuron's disclosed cash position was AUD 10.0 million at 31 December 2025, which the company described as about 22.5 months of cash used in Operating Activities based on first-half FY26 burn. That is the most recent balance stated in the filings reviewed here; a June 2026 figure was not located, so the runway at the end of FY26 is not established.

Half-year FY26 EBITDX excluding research and development was negative AUD 1.1 million, and Immuron received an AUD 1.1 million research and development tax incentive in February 2026. Market data services showed trailing twelve-month revenue of about AUD 7.5 million and a trailing net loss of roughly AUD 4.7 million, on about 326.7 million shares.

What to Watch

Immuron lodged its FY25 Appendix 4E on 29 August 2025, so audited FY26 accounts would ordinarily be expected around the end of August 2026, though no date was confirmed in the material reviewed. Those accounts should provide the 30 June 2026 cash balance, the full-year loss and the contribution from ProIBS and the Defense-funded work.

Risks

Scale is the central risk. At roughly AUD 11 million of market value and single-digit millions of revenue, Immuron has limited capacity to absorb a bad quarter, and its historical funding pattern has involved Equity issuance. Travelan is a discretionary travel-linked purchase, so any disruption to international travel flows feeds through quickly.

Outlook

Immuron enters the FY26 reporting window with a modestly growing commercial product, a cheaper operating model and two unpartnered clinical Assets . The near-term focus will be the audited accounts and the 30 June cash position, followed by any progress on the partnering timetable. Momentum, on the evidence available, is real but small.